Welcome to the UPF Digital Repository

Polycomb factor PHF19 controls cell growth and differentiation toward erythroid pathway in chronic myeloid leukemia cells

Show simple item record

dc.contributor.author García Montolío, Marc, 1991-
dc.contributor.author Ballaré, Cecilia Julia
dc.contributor.author Blanco, Enrique
dc.contributor.author Gutiérrez, Arantxa
dc.contributor.author Aranda Aragón, Sergio
dc.contributor.author Gómez, Antonio
dc.contributor.author Kok, Chung H.
dc.contributor.author Yeung, David T.
dc.contributor.author Hughes, Timothy P.
dc.contributor.author Vizán, Pedro
dc.contributor.author Di Croce, Luciano
dc.date.accessioned 2021-07-23T06:57:28Z
dc.date.available 2021-07-23T06:57:28Z
dc.date.issued 2021
dc.identifier.citation García-Montolio M, Ballaré C, Blanco E, Gutiérrez A, Aranda S, Gómez A et al. Polycomb factor PHF19 controls cell growth and differentiation toward erythroid pathway in chronic myeloid leukemia cells. Front Cell Dev Biol. 2021 Apr 29;9:655201. DOI: 10.3389/fcell.2021.655201
dc.identifier.issn 2296-634X
dc.identifier.uri http://hdl.handle.net/10230/48285
dc.description.abstract Polycomb group (PcG) of proteins are a group of highly conserved epigenetic regulators involved in many biological functions, such as embryonic development, cell proliferation, and adult stem cell determination. PHD finger protein 19 (PHF19) is an associated factor of Polycomb repressor complex 2 (PRC2), often upregulated in human cancers. In particular, myeloid leukemia cell lines show increased levels of PHF19, yet little is known about its function. Here, we have characterized the role of PHF19 in myeloid leukemia cells. We demonstrated that PHF19 depletion decreases cell proliferation and promotes chronic myeloid leukemia (CML) differentiation. Mechanistically, we have shown how PHF19 regulates the proliferation of CML through a direct regulation of the cell cycle inhibitor p21. Furthermore, we observed that MTF2, a PHF19 homolog, partially compensates for PHF19 depletion in a subset of target genes, instructing specific erythroid differentiation. Taken together, our results show that PHF19 is a key transcriptional regulator for cell fate determination and could be a potential therapeutic target for myeloid leukemia treatment.
dc.description.sponsorship This work was supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-75008-P and PID2019-108322GB-100), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), and from AGAUR (SGR 2017-2019). SA was funded by the Ramon y Cajal program of the Ministerio de Ciencia, Innovación y Universidades, the European Social Fund under the reference number RYC-2018-025002-I, and the Instituto de Salud Carlos III-FEDER (PI19/01814)
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Frontiers Media
dc.relation.uri https://creativecommons.org/licenses/by/4.0/
dc.rights © 2021 Marc García-Montolio et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms
dc.subject.other Leucèmia
dc.subject.other Genètica
dc.title Polycomb factor PHF19 controls cell growth and differentiation toward erythroid pathway in chronic myeloid leukemia cells
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3389/fcell.2021.655201
dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/BFU2016-75008-P
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking